Interferon-α in high-risk melanoma patients

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 4, Issue 6, 2004, Pages 667-676

  Cormier, Janice N ^a   Xing, Yan ^a   Ross, Merrick I ^a   Cantor, Scott B ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cost effectiveness; Interferon ; Melanoma

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; GANGLIOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; KEYHOLE LIMPET HEMOCYANIN; PEPTIDE DERIVATIVE;

ANOREXIA; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONCENTRATION LOSS; DRUG COST; DRUG DOSE REGIMEN; DRUG FEVER; DRUG MEGADOSE; FATALITY; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEALTH ECONOMICS; HIGH RISK PATIENT; HUMAN; INCIDENCE; IRRITABILITY; LIFE EXPECTANCY; LIVER TOXICITY; LYMPH NODE METASTASIS; MELANOMA; MENTAL DISEASE; MONOTHERAPY; MOOD DISORDER; MUSCLE WEAKNESS; MYALGIA; NAUSEA; PATIENT COMPLIANCE; PRIMARY PREVENTION; PROGNOSIS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN CANCER; SKIN ULCER; SUICIDE ATTEMPT; SUN EXPOSURE; SURVIVAL RATE; VOMITING;

EID: 9944223688     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.4.6.667     Document Type: Review

References (56)

1. World Health Organization. INTERSUN - Global UV project (2004).
2. Cancer Facts & Figures. American Cancer Society (2004).
3. Howe HL, Wingo PA, Thun MJ et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J. Natl Cancer Inst. 93(11), 824-842 (2001).
4. Berwick M. Patterns of sun exposure which are causal for melanoma. In: Melanoma Critical Debates. Bishop J, Gore M (Eds). Blackwell Science, Oxford, UK, 3-15 (2002).
5. Crowson AN, Magro CM, Sanchez-Carpintero I, Mihm MC Jr. The precursors of malignant melanoma. In: Cancers of the Skin: Proceedings of the 8th World Congress. Drummer R, Nestle FO (Eds). Springer, NY, USA, 75-84 (2002).
6. Trask PC, Paterson AG, Hayasaka S, Dunn RL, Riba M, Johnson T. Psychosocial characteristics of individuals with non-Stage IV melanoma. J. Clin. Oncol. 19(11), 2844-2850 (2001).
7. Geller AC, Annas GD. Epidemiology of melanoma and nonmelanoma skin cancer. Semin. Oncol. Nurs. 19(1), 2-11 (2003).
8. Lotze MT, Dallal RM, Kirkwood JM et al. Cutaneous melanoma. In: Cancer: Principles & Practice of Oncology. DeVita VT, Hellman S, Rosenberg SA (Eds). Lippincott Williams & Wilkins, PA. USA, 2012-2069 (2001).
9. American Joint Committee on Cancer. Cancer Staging Handbook from the AJCC Cancer Staging Manual. Springer, NY, USA (2002).
10. Balch CM, Soong S-J, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer Melanoma Staging System. J. Clin. Oncol. 19(16), 3622-3634 (2001).
11. Morton DL, Wen DR, Wong JH et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch. Surg. 127(4), 392-399 (1992).
12. Reintgen D, Cruse CW, Wells K et al. The orderly progression of melanoma nodal metastases. Ann. Surg. 220(6), 759-767 (1994).
13. Albertini JJ, Cruse CW, Rapaport D et al. Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann. Surg. 223(2), 217-224 (1996).
14. Thompson JF, McCarthy WH, Bosch CM et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res. 5(4), 255-260 (1995).
15. Gershenwald JE, Thompson W, Mansfield PF et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 Stage I or II melanoma patients. J. Clin. Oncol. 17(3), 976-983 (1999).
16. Gershenwald JE, Tseng CH, Thompson W et al. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery 124(2), 203-210 (1998).
17. Yu LL, Flotte TJ, Tanabe KK et al. Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer 86(4), 617-627 (1999).
18. Gershenwald JE, Colome MI, Lee JE et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with Stage I or II melanoma. J. Clin. Oncol. 16(6), 2253-2260 (1998).
19. Balch CM, Buzaid AC, Soong S-J et al. Final version of the American Joint Committee on Cancer Staging System for cutaneous melanoma. J. Clin. Oncol. 19(16), 3635-3648 (2001).
20. Ak I, Stokkel MP, Bergman W, Pauwels EK. Cutaneous malignant melanoma: clinical aspects, imaging modalities and treatment. Eur. J. Nucl. Med. 27(4), 447-458 (2000).
21. Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann. Surg. Oncol. 7(2). 160-165 (2000).
22. Gershenwald JE, Prieto VG, Colome-Grimmer MI et al. The prognostic significance of microscopic tumor burden in 945 melanoma patients undergoing sentinel lymph node biopsy. Proceedings from the American Society of Clinical Oncology. New Orleans, LA, USA (2000).
23. Pawlik TM, Sondak VK. Malignant melanoma: current state of primary and adjuvant treatment. Crit. Rev. Oncol. Hematol. 45(3), 245-264 (2003).
24. 2a in high-risk resected malignant melanoma. J. Clin. Oncol. 22(1), 53-61 (2004).
25. 2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 358, 866-869 (2001).
26. Wheatley K, Hancock B, Gore M, Suciu S, Eggermont A. Interferon-α as adjuvant therapy for melanoma: a meta-analysis of the randomised trials. Proc. Am. Soc. Clin. Oncol. (2001).
27. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat. Rev. 29(4), 241-252 (2003).
28. 2a in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J. Clin. Oncol. 18(12), 2444-2458 (2000).
29. 2a in high risk melanoma - the Scottish study. Br. J. Cancer 84(9), 1146-1149 (2001)
30. Kleeberg UR, Broecker EB, Chartier C et al. Adjuvant trial in melanoma patients comparing rIFN-α to rIFN-r to Iscador to a control group after curative resection of high risk primary (> = 3 mm) or regional lymphnode metastasis (EORTC 18871). Eur. J. Cancer 135(Suppl. 4), S82 (1999).
31. 2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Co-operative Group on Melanoma. Lancet 351, 1905-1910 (1998).
32. 2a treatment in resected primary Stage II cutaneous melanoma. Austrian Malignant Melanoma Co-operative Group. J. Clin. Oncol. 16(4), 1425-1429 (1998).
33. 2a in selected patients with malignant melanoma. J. Clin. Oncol. 13(11), 2776-2783 (1995).
34. 2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Co-operative Oncology Group Trial EST 1684. J. Clin. Oncol. 14(1), 7-17 (1996).
35. 2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected Stage IIb-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 19(9), 2370-2380 (2001).
36. 2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Co-operative Oncology Group Phase II Trial E2696. J. Clin. Oncol. 19(5), 1430-1436 (2001).
37. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern co-operative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res. 10(5), 1670-1677 (2004).
38. Schuchter LM. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose? J. Clin. Oncol. 22(1), 7-10 (2004).
39. 2b. J. Clin. Oncol. 22(1), 11-14 (2004).
40. 2a. American Society of Clinical Oncology, VA, USA (2001).
41. 2b therapy. J. Clin. Oncol. 20(17), 3703-3718 (2002).
42. Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Mood and cognitive side effects of interferon-α therapy. Semin. Oncol. 25(1 Suppl. 1), 39-47 (1998).
43. 2b for high-risk melanoma patients using intergroup clinical trial data. J. Clin. Oncol. 20(5), 1311-1318 (2002).
44. 2b treatment. J. Clin. Oncol. 19(3), 812-823 (2001).
45. 2b in high-risk melanoma based on projections from Eastern Co-operative Oncology Group 1684. J. Clin. Oncol. 15(6), 2351-2358 (1997).
46. Messori A, Becagli P, Trippoli S, Tendi E. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma. Eur. J. Cancer 33(9), 1373-1379 (1997).
47. Gonzalez-Larriba JL, Serrano S, Alvarez-Mon M et al. Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain. Eur. J. Cancer 36(18), 2344-2352 (2000).
48. Crott R, Ali F, Burdette-Radoux S. Cost-utility of adjuvant high-dose interferon α therapy in Stage III cutaneous melanoma in Quebec. Value Health 7(4), 423-432 (2004).
49. Crott R, Ali F, Burdette-Radoux S. Measurement of utility-based quality-of-life in adjuvant interferon therapy in melanoma. Quality Life Res. 8, 284 (1999).
50. Crott R. Cost effectiveness and cost utility of adjuvant interferon α in cutaneous melanoma: a review. PharmacoEconomics 22(9), 569-580 (2004).
51. Sabel MS, Sondak VK. Is there a role for adjuvant high-dose interferon-α-2b in the management of melanoma? Drugs 63(11), 1053-1058 (2003).
52. Eggermont AMM, Keilholz U. What is the role of biological response modifiers in the treatment of melanoma? In: Melanoma: Critical Debates. Newton Bishop JA, Gore M (Eds). Blackwell Science Ltd, Oxford, UK, 195-211 (2002).
53. Retsas S. Adjuvant therapy of malignant melanoma: is there a choice? Crit. Rev. Oncol. Hematol. 40(2), 187-193 (2001).
54. Hersey P. Will vaccines really work for melanoma? In: Melanoma: Critical Debates. Newton Bishop JA, Gore M (Eds). Blackwell Science, Oxford, UK, 212-229 (2002).
55. Sondak VK, Sosman J, Unger JM et al. Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035. Proceedings from the American Society of Clinical Oncology. New Orleans, LA, USA (2004).
56. Mooney MM, Mettlin C, Michalek AM, Petrelli NJ, Kraybill WG. Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis. Cancer 80(6), 1052-1064 (1997).